Holen Sie sich die Stockscreener-App
17.66
3.27%
0.56
Handel nachbörslich:
17.33
-0.33
-1.87%
Schlusskurs vom Vortag:
$17.10
Offen:
$17.1
24-Stunden-Volumen:
2.93M
Relative Volume:
1.50
Marktkapitalisierung:
$6.15B
Einnahmen:
$3.05B
Nettoeinkommen (Verlust:
$181.32M
KGV:
47.35
EPS:
0.373
Netto-Cashflow:
$186.11M
1W Leistung:
-4.33%
1M Leistung:
+3.82%
6M Leistung:
+20.71%
1J Leistung:
+95.79%
1-Tages-Spanne:
$16.77
$17.67
1-Wochen-Bereich:
$16.77
$18.81
52-Wochen-Spanne:
$8.96
$19.26
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
17.66 | 5.96B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
17.41 | 55.82B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.80 | 43.73B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.74 | 42.51B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
73.54 | 31.14B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
511.72 | 22.11B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | UBS | Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase - Stock Titan
Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A - Stock Titan
Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal - Stock Titan
AMRX (AMRX) plans Rule 144 resale of 146,403 equity compensation shares - Stock Titan
Amneal Pharmaceuticals, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine? - finance.yahoo.com
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? - finance.yahoo.com
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? - finance.yahoo.com
Amneal Pharmaceuticals Inc (AMRX) Shares Fall 4.3% -- GF Value S - GuruFocus
Charles Schwab Corp (AMRX): holder files Form 144 for 2.92M-share sale - Stock Titan
Amneal closes $1.1B Kashiv Biosciences acquisition - NJBIZ
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why - finance.yahoo.com
Amneal Pharma completes acquisition of Kashiv BioSciences - Pharmabiz.com
California State Teachers Retirement System Purchases 56,588 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals Adds $350 Million Incremental Term Loan to Fund Kashiv Acquisition - TradingView
Amneal completes acquisition of Kashiv BioSciences By Investing.com - Investing.com UK
Amneal acquires Kashiv BioSciences, creating global biosimilars leader - Telangana Today
Amneal completes acquisition of Kashiv BioSciences - Investing.com
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader - The Manila Times
Amneal's New Global Platform Spans Biosimilar Research to Commercialization - Stock Titan
Oliver Luxxe Assets LLC Has $1.46 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Renaissance Technologies LLC Acquires 260,237 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality - webull.com
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock? - finance.yahoo.com
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Segall Bryant & Hamill LLC Sells 113,969 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Evaluating a Robust 7.43% Potential Upside - DirectorsTalk Interviews
Amneal Reprices $2.08B Term Loan, Cuts Margin 50 Bps; Sees ~$12M Annual Interest Savings - TradingView
UBS raises Amneal Pharmaceuticals price target on biosimilar growth - Investing.com
UBS Adjusts Price Target on Amneal Pharmaceuticals to $25 From $23, Maintains Buy Rating - finance.yahoo.com
amneal pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Bank of New York Mellon Corp - MarketBeat
Sei Investments Co. Has $8.78 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Dimensional Fund Advisors LP Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure - Sahm
Amneal Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q2 Revenue $796.2M, vs. FactSet Est of $768.2M - marketscreener.com
Amneal: Q2 Earnings Snapshot - 10TV
Amneal Reports Second Quarter 2026 Financial Results - GlobeNewswire
Amneal Debt Repricing Expected to Save About $12M a Year - Stock Titan
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1 - finance.yahoo.com
Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD By Investing.com - Investing.com Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighHere's What Happened - MarketBeat
Amneal Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals, Inc. Class A Revenue Breakdown – FWB:2DT - TradingView
AMRX|Amneal Pharmaceuticals Inc|Price:17.920|Chg%:-0.050 - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Institutional Confidence - TradingKey
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.17%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):